A body of clinical research has demonstrated the potential use of psychedelic compounds, such as psilocybin and ketamine, as a treatment for a range of mental illnesses including depression, addiction, and post-traumatic stress disorder (PTSD), among many others.
ETF Strategy writes that research has helped break down regulatory barriers, resulting in a growing number of firms entering the psychedelics industry and the portfolio breadth necessary for an ETF.